Jeremie Calais

• Using real-world clinical outcomes to provide insights into patient populations, treatment efficacy and long-term safety

• Enhancing trial design through optimal patient selection, dosing strategies and endpoints

• Guiding potential personalized treatment strategies

• Understanding whether we can do better than the approved fixed dosing schedule of Lu177-PSMA-617 for mCPRC patients: 7.4 Gbq per cycle, 6-week time interval between each cycle, up to 6 cycles max

• Reviewing literature and early findings from the UCLA IITs FLEX MRT NCT06216249 and RE-LuPSMA NCT06288113

• Exploring future considerations for optimal dosing